Floatz logo

Capivasertib

PTEN

AstraZenecaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the PTEN cohort.

Asset / SponsorPhaseRating
Enzalutamide
M.D. Anderson Cancer Center
Phase 1CC
Alpelisib
M.D. Anderson Cancer Center
Phase 1CC
Serabelisib
Faeth Therapeutics
Phase 1CC
Talzenna
The University of Hong Kong
Phase 2NR

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Advanced Non-small-cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →